Brief: Biofrontera Provides Update On Clinical Developments
22/06/2021 14:03
June 22 (Reuters) - BIOFRONTERA AG B8FGn.DE :
* WITH REGARD TO APPROVAL PROCESS OF BF-RHODOLED®, FDA HAS
CONFIRMED THAT DATA ARE SUFFICIENT FOR SUBMISSION AND THAT
EVALUATION PROCESS WILL BE INITIATED.
* FDA AGREED WITH PROPOSAL TO OBSERVE SYSTEMIC AND LOCAL
SIDE
EFFECTS DURING TREATMENT WITH THREE TUBES OF AMELUZ® IN 100
PATIENTS; STUDY SCHEDULED TO START IN H2 2021.
Source text for Eikon: ID:nPexTJ1Q6a
Further company coverage: B8FGn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biofrontera AG
See all newsBrief: Biofrontera Says Co And Units Have Entered Into An Agreement With Biofrontera Inc About How To Settle Payment Obligations By Biofrontera Inc
Brief: Biofrontera AG Says Legal Dispute On Import In USA Will Result In Revised Outlook
Brief: Biofrontera AG Resolves Capital Increase From Authorized Capital
Brief: Biofrontera AG Says Plans Capital Reduction And Considers Subsequent Capital Increase From Authorized Capital
Brief: Biofrontera AG Says FY 2022 Total Revenue Amounted To EUR 25.7 Million